Isabel Olivera-Martinez’s Post

Thanks, Richard! Today, I presented my recent results and insights on transcriptomic MYC activation in CLL. Long story short, high MYC transcriptomic activation is associated with increased interactions with the TME, suggesting MYC as an orchestrator of TME interactions and explaining why it is linked to various cellular processes. #eha #eha2024

📢All 12 manuscripts in the #SpecialIssue “#Hematologic #Malignancies: Challenges from Diagnosis to Treatment”, led by Dr. Ioanna Sakellari and Dr. Eleni Gavriilaki, Hematology Department and Dr. Eleni Gavriilaki, have been published! 🎉🎉 📌You are welcome to read via the following link: https://lnkd.in/dyADYnGy

Mark your calendars for a live webinar hosted by Fortis Institute of Blood Disorder on Innovations in Hematology. Join us on May 17th, 2024, from 7 PM to 8 PM and gain invaluable knowledge from leading specialists Dr. Jayastu Senapati and Dr. Nikhil M Kumar. Discover new technologies and innovative practices that are shaping the future of hematology. #AtFortisWeCare #FortisHealthcare #Webinar

New publication 📝 Retrospective analysis published in Hematology provides new insights for #AcuteLymphoblasticLeukemia, see: https://loom.ly/vnLhcDM #ALLsm #leusm #MedEducation

Middle East Master Class in Hematology As a Panelist Jan.2024

NEW #Thalassemia Sessions from #ASH23🩸 💬 In this session, leading experts Maria Domenica Cappellini & Kevin Kuo discuss exciting updates in #thalassemia presented at the 2023 ASH Annual Meeting and Exposition The experts cover several topics, including the promise of novel #genetherapies, ongoing #clinicaltrials in the field, and the value of #precisionmedicine 🔬 Take a look 👉 https://lnkd.in/e2-JsM7Y #HemOnc #MPNsm American Society of Hematology

Join Kx Advisors in Madrid for EHA 2024, hosted by the European Hematology Association (EHA)! Connect with Nikil D. Kumar and Eleanor (Tyler) Maughan, PhD to learn more about how Kx Advisors can help you navigate the increasingly complex world of #hematology!   #EHA2024 #HematologyResearch 

#Congress | 🔎 What subjects were amplified by #HCPs through social media during #EHA2024? In June, took place the European Hematology Association (EHA) 2024 Hybrid Congress. The following pages provide a brief overview of the volume of conversations, the share of voice of clinical trials most discussed, or top hashtags. Moreover, discover a focus on #multiplemyeloma with the topics of discussions. Access the SML EHA2024 full report by clicking this link 👉 https://lnkd.in/e6-MYzHj

We are excited to provide updated clinical safety and efficacy data from 7 transfusion-dependent beta thalassemia patients treated with renizgamglogene autogedtemcel (reni-cel) in the Phase 1/2 EdiThal clinical trial at European Hematology Association (EHA) annual congress. Treated patients had early and robust increases of total hemoglobin (Hb) and fetal hemoglobin, with total Hb rising to or above the transfusion independence threshold of 9.0 g/dL. All patients have been transfusion free for a range of 4.1 to 12.8 months after receiving the last red blood cell transfusion at 0.5–2.2 months post-reni-cel infusion. Reni-cel was well-tolerated and continues to demonstrate a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. #BetaThalassemia #Biotechnology #Cas12a #CellTherapy #ClinicalTrials #CRISPR #EHA #GeneEditing #Hematology

Today we are working at conference EHA-KCS Hematology Tutorial on Recent Advances in Lymphoid and Myeloid Malignancies